Skip to main content

Table 7 Relation between type of primary endpoint and effectiveness

From: Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?

  Effectiveness  
Survival benefit > 3 months Survival benefit < 3 months, unknown magnitude or no benefit Total
Primary endpoint OS or surrogate endpoint for OS 3 1 4
PFS, RFS, TTP, ORR 3 3 6
  Total 6 4 10